Evidence map›Paper›PMID 42219614›Full record

Trial reportJournal of applied clinical medical physics2026

Investigating Setup Error Differences between Conventional and Ultra-Hypofractionated Whole Pelvis Radiation Therapy: A Secondary Analysis from the HOPE Randomized Clinical Trial.

Bryan Schaly, Lucas C Mendez, Maha Khawaja, Alec Black, Andrew Warner, Douglas A Hoover

Registry-linked trialAbstract readClinical Trial, Phase IIComparative StudyMulticenter Study
In one paragraph

Trial report in Journal of applied clinical medical physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04197141 (Is Hypofractionated Whole-Pelvis Radiotherapy), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04197141 phase2active not recruitingnot on this map

Is Hypofractionated Whole-Pelvis Radiotherapy (WPRT) as Well Tolerated as Conventionally-Fractionated WPRT in Prostate Cancer Patients? (HOPE-Trial)

TypeinterventionalSponsorLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sRan2020 to 2027Enrolled58ConditionsProstate CancerArmsConventionally-fractionated WPRT, Hypofractionated WPRT
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Bryan SchalyDepartment of Radiation Oncology, London Health Sciences Centre, London, Ontario, Canada.
Lucas C MendezDepartment of Radiation Oncology, London Health Sciences Centre, London, Ontario, Canada.
Maha KhawajaDepartment of Medical Biophysics, Western University, London, Ontario, Canada.
Alec BlackDepartment of Radiation Oncology, London Health Sciences Centre, London, Ontario, Canada.
Andrew WarnerDepartment of Radiation Oncology, London Health Sciences Centre, London, Ontario, Canada.
Douglas A HooverDepartment of Radiation Oncology, London Health Sciences Centre, London, Ontario, Canada.

Funding

AbbVie CARO Uro-Oncologic Radiation Awards
6 · The paper itself

Abstract

introductionThe multi-institutional HOPE trial (NCT04197141) compared conventional (25 fractions over 5 weeks) to ultra-hypofractionated (5 fractions over 1.5 weeks) whole pelvis radiotherapy for unfavorable intermediate and high/very high-risk prostate cancer patients treated with brachytherapy boost. Within this randomized controlled trial, we investigated setup errors for clinical target volumes corresponding to the prostate (CTVp) and nodes (CTVn).

methodsFifty-four patients treated within a single institution were analyzed, with 28 treated on the ultra-hypofractionated arm and 26 on the conventional fractionation arm. Prior to treatment, three fiducial markers were implanted into the prostate for daily cone-beam computed tomography (CBCT) matching. All plans were delivered using volumetric modulated arc therapy with a uniform 6-mm PTV margin. For all treatment fractions, average fiducial matching errors were measured for CTVp, while errors to CTVn were determined based on the difference between the treatment position and an automatic match to bone. Asymmetric PTV margins to account for prostatic and nodal setup errors were calculated using the van Herk formalism.

resultsMedian (interquartile range [IQR]) 3D errors for CTVp were 1.4 (0.8-2.5) mm for conventional versus 1.2 (0.7-1.9) mm for the ultra-hypofractionatated arms (p = 0.013), while for CTVn they were 2.8 (1.6-4.2) mm and 2.9 (2.2-4.4) mm, respectively (p = 0.07). Between arms, statistically significant differences in setup errors were noted in all directions for CTVp and in the anterior-posterior direction for CTVn (p < 0.05). To account for setup error, the required PTV margins in the anterior-posterior/superior-inferior/lateral directions were 2.8/3.8/0.8 and 2.7/3.0/1.0 mm for conventional and ultra-hypofractionated treatments, respectively; for elective nodes, margins were 5.4/4.4/0.7 and 5.7/4.9/1.0 mm, respectively.

conclusionsThe 6-mm PTV margin around the CTVn is appropriate to account for residual setup error while the margin around the CTVp could be reduced, assuming other sources of error are controlled. The residual 3D errors for the prostate were statistically significantly smaller in the ultra-fractionated regimen, which was potentially due to longer image matching times and/or the higher percentage of patients treated with a 6-DOF couch in that arm. However, this came at the expense of slightly larger nodal PTV margins in the ultra-hypofractionated arm. These findings highlight the need for individual centers to independently quantify their treatment uncertainties, as measurable differences were observed between treatment arms despite identical image guidance protocols.

Indexed as

BrachytherapyProstatic NeoplasmsRadiotherapy Planning, Computer-AssistedRadiotherapy Setup ErrorsCone-Beam Computed TomographyDose Fractionation, RadiationFiducial MarkersHumansMaleOrgans at RiskPrognosisRadiotherapy DosageRadiotherapy, Intensity-Modulatedfiducial markersplanning target volume marginsprostate cancersetup errorsultra‐hypofractionation

Identifiers

PMID42219614
PMCPMC13239894

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.